This provider's $8.0M in total Medicare payments ranks in the 99th percentile of Diagnostic Radiology providers nationally.
Medicare payments to this provider grew 1819% from 2017 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 356% in 2023
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2017 | $263.03 | $75.14 | 3.50x | $187.89 | $211.4K | 2.8K | 17 |
| 2018 | $302.59 | $90.25 | 3.35x | $212.34 | $646.5K | 7.2K | 44 |
| 2019 | $444.93 | $133.97 | 3.32x | $310.96 | $879.3K | 6.6K | 36 |
| 2020 | $496.09 | $144.64 | 3.43x | $351.45 | $762.5K | 5.3K | 32 |
| 2021 | $422.74 | $115.73 | 3.65x | $307.01 | $602.0K | 5.2K | 34 |
| 2022 | $555.22 | $175.99 | 3.15x | $379.23 | $889.3K | 5.1K | 33 |
| 2023 | $440.96 | $150.14 | 2.94x | $290.82 | $4.1M | 27.0K | 38 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| A9607 | Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie | 15.8K | $3.1M | $193.39 | 2.57x |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | 3.0K | $1.9M | $650.35 | 3.21x |
| A9596 | Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | 629 | $519.4K | $825.70 | 3.15x |
| A9584 | Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | 247 | $480.1K | $1.9K | 3.01x |
| A9588 | Fluciclovine f-18, diagnostic, 1 millicurie | 185 | $415.0K | $2.2K | 2.90x |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 163 | $213.7K | $1.3K | 2.47x |
| A9587 | Gallium ga-68, dotatate, diagnostic, 0.1 millicurie | 598 | $178.6K | $298.58 | 3.04x |
| 78306 | Nuclear medicine study of bone and/or joint whole body | 914 | $160.9K | $176.04 | 3.01x |
| 78816 | Nuclear medicine study whole body with ct scan | 304 | $150.9K | $496.49 | 3.48x |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1.2K | $112.7K | $92.78 | 4.34x |
| 74177 | Ct scan of abdomen and pelvis with contrast | 913 | $83.2K | $91.15 | 8.55x |
| 78072 | Nuclear medicine study of parathyroid with spect and ct scan | 223 | $76.9K | $344.90 | 5.17x |
| 78608 | Nuclear medicine study of brain with metabolic evaluation | 44 | $46.0K | $1.0K | 3.01x |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 137 | $43.1K | $314.25 | 3.89x |
| 78227 | Nuclear medicine study of liver and bile duct system with use of drugs | 198 | $42.0K | $211.98 | 3.15x |
| A9597 | Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified | 11 | $40.9K | $3.7K | 3.16x |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 139 | $36.8K | $264.86 | 3.02x |
| 78264 | Nuclear medicine study of stomach to assess emptying | 181 | $36.6K | $202.33 | 2.48x |
| 71260 | Ct scan of chest with contrast | 593 | $35.2K | $59.35 | 5.51x |
| 78607 | Nuclear medicine study of brain | 115 | $33.1K | $287.87 | 3.21x |
This provider submits charges 3.15 times higher than what Medicare actually pays.
A markup ratio of 3.15x means for every $100 Medicare pays, this provider initially charges $315. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data